Article in NSC July/August 2021
Leading Pharmaceutical company GlaxoSmithKline is continuing investment at its Barnard Castle site with rapid construction of a new steel-framed cold store and purified water plant extension.
Following on from the major investment in its manufacturing sites announced in 2016, GlaxoSmithKline (GSK) continues to invest in the Barnard Castle site to support New Product Introduction programmes and existing facilities. The latest investment includes construction of additional cold storage capacity and a new purified water plant room extension. Barnard Castle is one of GSK’s largest secondary manufacturing sites, employing around 1,000 people. The site supplies nearly half a million packs of products per day to 140 global markets. The recent major investment included Q Block, a new advanced aseptic manufacturing facility that will be utilised for delivery of GSK’s pipeline of new biopharmaceutical products.
The steel-framed structure that houses the cold store and purified water plant room extension measures 26m-long × 15m-wide × 11.2m-high and is connected to the existing Q Block structure. GSK Project Manager Lauren Du Bourg says: “The original plans for the building included the option for future cold store expansion, which would support capacity increase for the site’s biopharmaceutical new product pipeline.”
One of the main challenges for the site team, including steelwork contractor Border Steelwork Structures (BSS), was completing the erection programme in and around a functioning biopharmaceutical building. The main steel-framed facility was completed and qualified in 2019/20 and is currently undergoing a final performance qualification. “The steelwork installation required a 40t-capacity crane to deliver our complete package in a three-week programme,” explains BSS Contracts Director Stuart Airey. “It was a relatively small building extension, but safety was upmost priority working on a live GSK site. We had our own Contracts Manager onsite throughout the works who coordinated very well with the GSK site team, and this resulted in a very good outcome to the schedule.”
The new steelwork gains its stability from the existing steel-framed structure, as it connects to an existing frame on three sides, and along the longest 26m-long elevation it also includes a movement expansion joint. “In order to have continuity of movement, we had to have a dog-leg connection to the new perimeter columns that form a new continuing expansion joint,” adds BakerHicks Engineer William Bancroft. “Forming part of the cold room extension, a series of 9m-long columns connect to this new movement joint via a sliding connection. They are spaced at 1.2m centres as they support the roof cladding.”
Overall, the cold store is a single storey structure, and its frame is completed by further internal spans of 8.5m. However, the internal space is supplemented by additional floorspace in the adjoining existing structure. “The cold store will be utilised for storage of cold chain pharmaceutical products, including both biopharmaceutical and chemical drug products. The capacity demands on site are increasing as our new pipeline of biopharmaceutical products deliver a range of new medicines including key oncology treatments,” explains GSK Engineering Director Nigel Wood.
GSK’s Barnard Castle extension is due to complete later this year.
|
Structural Engineer |
BakerHicks |
|
Steelwork Contractor |
Border Steelwork Structures |
|
Main Client |
GlaxoSmithKline |